Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia

Stephen P. Hunger, Mignon L. Loh, James A. Whitlock, Naomi J. Winick, William L. Carroll, Meenakshi Devidas, Elizabeth A. Raetz

Research output: Contribution to journalReview article

93 Scopus citations


Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/μl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

Original languageEnglish (US)
Pages (from-to)957-963
Number of pages7
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 1 2013



  • Acute lymphoblastic leukemia (ALL)
  • COG ALL trials

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Hunger, S. P., Loh, M. L., Whitlock, J. A., Winick, N. J., Carroll, W. L., Devidas, M., & Raetz, E. A. (2013). Children's oncology Group's 2013 blueprint for research: Acute lymphoblastic leukemia. Pediatric Blood and Cancer, 60(6), 957-963.